Zhejiang Hisun Pharmaceutical Temettü

Temettü kriter kontrolleri 0/6

Zhejiang Hisun Pharmaceutical şu anda temettü ödemiyor.

Anahtar bilgiler

Temettü verimi

1.1%

Geri Alım Getirisi

Toplam Hissedar Getirisi	1.1%
Gelecekteki Temettü Verimi	0.7%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	CN¥0.170
Ödeme oranı	0%

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Shares Lagging The Industry But So Is The Business

Sep 26

These 4 Measures Indicate That Zhejiang Hisun Pharmaceutical (SHSE:600267) Is Using Debt Reasonably Well

Apr 30

Investors Don't See Light At End Of Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Tunnel

Mar 29

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: 600267 şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: 600267 şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Zhejiang Hisun Pharmaceutical Piyasaya Karşı Temettü Getirisi

600267 temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (600267)	0%
Pazarın Alt %25'i (CN)	0.6%
Pazarın En İyi %25'i (CN)	2.2%
Sektör Ortalaması (Pharmaceuticals)	1.7%
Analist tahmini (600267) (3 yıla kadar)	0.7%

Önemli Temettü: 600267 şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, 600267 şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: 600267 CN piyasası için dikkate değer bir temettü ödemiyor.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: 600267 herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Zhejiang Hisun Pharmaceutical Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.068 (vs CN¥0.031 in 3Q 2023)

Zhejiang Hisun Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Shares Lagging The Industry But So Is The Business

Price target decreased by 10.0% to CN¥6.30

Second quarter 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.18 in 2Q 2023)

Zhejiang Hisun Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 20, 2024

Zhejiang Hisun Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024

These 4 Measures Indicate That Zhejiang Hisun Pharmaceutical (SHSE:600267) Is Using Debt Reasonably Well

Full year 2023 earnings released: CN¥0.08 loss per share (vs CN¥0.42 profit in FY 2022)

Zhejiang Hisun Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Investors Don't See Light At End Of Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Tunnel

Investor sentiment deteriorates as stock falls 17%

Zhejiang Hisun Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 16, 2024

Price target decreased by 13% to CN¥8.30

New minor risk - Financial position

Third quarter 2023 earnings released: EPS: CN¥0.031 (vs CN¥0.01 in 3Q 2022)

Zhejiang Hisun Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 28, 2023

Second quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.15 in 2Q 2022)

Zhejiang Hisun Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 22, 2023

Full year 2022 earnings released: EPS: CN¥0.42 (vs CN¥0.43 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.01 (vs CN¥0.19 in 3Q 2021)

Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) announces an Equity Buyback for CNY 195 million worth of its shares.

Taizhou Jiaojiang State Owned Asset Operation Group Co Ltd agreed to acquire 4% stakes in Zhejiang Hisun Animal Health-care Products Co., Ltd. from Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) for CNY 100 million.

Second quarter 2022 earnings released: EPS: CN¥0.27 (vs CN¥0.13 in 2Q 2021)

Shanghai Yuanxun Enterprise Management Center and Hong Kong Summit Nutrition Limited agreed to acquire 34.72% interest of Zhejiang Hisun Sulikang Biotechnology Co., Ltd from Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) for RMB 17.4 million.

Investor sentiment improved over the past week

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.43 (vs CN¥0.43 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.11 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.32 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.074 loss in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.43 (vs CN¥0.096 in FY 2019)

New 90-day low: CN¥15.49

Zhejiang Hisun Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 23, 2021

New 90-day high: CN¥18.41

CHIPSCREEN and HISUN Reach A Strategic Cooperation

New 90-day low: CN¥15.63

Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) signed letter of intent to acquire the remaining 49% stake in Hanhui Pharmaceutical Co., Ltd. from Hillhouse Capital Management, Ltd for CNY 4.4 billion.

Earnings released

New 90-day high - CN¥18.90

Zhejiang Hisun Pharmaceutical Co., Ltd. announced a financing transaction

Zhejiang Hisun Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 18, 2020

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin